Altria Group, Inc. (NYSE:MO)’s beta now stands at 0.44 and when compared to its 200-day moving average and its 50-day moving average, MO price stands -7.43% below and -10.04% below respectively. The stock dropped by -25.21% or -$18.75 from its last recorded high of $74.38 which it attained on December 19 to close at $55.63 per share. Over the past 52 weeks, the shares of Altria Group, Inc. has been trading as low as $53.91 before witnessing a massive surge by 3.19% or $1.72. This price movement has led to the MO stock receiving more attention and has become one to watch out for. It dipped by -0.09% on Tuesday and this got the market worried. Its average daily volatility for this week is 2.56% which is less than the 2.6% recorded over the past month.
Altria Group, Inc. (MO) sank -7.28% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -15.49% and is now down by -22.1% since start of this year. A look at its monthly performance shows that the stock has recorded a -9.26% fall over the past 30 days. Its equity price dipped by -6.22% over the past three months which led to its overall six-month decrease to stand at -0.45%.
Experts from research firms are bullish about the near-term performance of Altria Group, Inc. with most of them predicting a $67.62 price target on a short-term (12 months) basis. The average price target by the analysts will see a 21.55% rise in the stock and would lead to MO’s market cap to surge to $127.13B. The stock has been rated an average 2.2, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 17 analysts that track Altria Group, Inc. (NYSE:MO) and find out that 7 of them rated it as a Hold. 10 of the 10 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.
A look at MO technical analysis shows that its 14-day Relative Strength Index (RSI) is in a oversold zone after reaching 25.88 point. Its trading volume has added 2440541 shares compared to readings over the past three months as it recently exchanged 10160541 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 7720000 shares, and this is 1.32 times the normal volume.
The price of Neos Therapeutics, Inc. (NASDAQ:NEOS) currently stands at $1.74 after it went down by $-0.15 or -7.94% and has found a strong support at $1.63 a share. If the NEOS price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $1.52 mark would also be bad for the stock as it means that the stock would plunge by 12.64% from its current position. However, if the stock price is able to trade above the resistance point around $1.87, then it could likely surge higher to try and break the upward resistance which stands at $2 a share. Its average daily volatility over the past one month stands at 10.9%. The stock has plunged by 5.11% from its 52-weeks high of $1.651 which it reached on Jan. 22, 2018. In general, it is -6.9% above its 52-weeks lowest point which stands at $1.86 and this setback was observed on Nov. 20, 2018.
Analysts have predicted a price target for Neos Therapeutics, Inc. (NEOS) for 1 year and it stands at an average $11.2/share. This means that it would likely increase by 543.68% from its current position. The current price of the stock has been moving between $1.651 and $1.89. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $5. On the other hand, one analyst is super bullish about the price, setting a target as high as $20.
Analysts view Neos Therapeutics, Inc. (NASDAQ:NEOS) as a Buy, with 2 consensus rating. Reuters surveyed 6 analysts that follow NEOS and found that 1 of those analysts rated the stock as a Hold. The remaining 5 were divided, with 5 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Neos Therapeutics, Inc. (NEOS) shares or sell it if they already own it.